Peripheral blood levels of thyroglobulin mRNA and serum thyroglobulin concentrations after radioiodine ablation of multinodular goiter with or without pre-treatment with recombinant human thyrotropin
- PMID: 17848834
- DOI: 10.1007/BF03346345
Peripheral blood levels of thyroglobulin mRNA and serum thyroglobulin concentrations after radioiodine ablation of multinodular goiter with or without pre-treatment with recombinant human thyrotropin
Abstract
We investigated the effect of therapeutic doses of radioiodine (RAI) on peripheral serum messenger thyroglobulin RNA (Tg mRNA) and serum thyroglobulin (sTg) in patients with multinodular goiter (MNG) preceded or not by treatment with recombinant human TSH (rhTSH). Fourteen patients with large MNG (91-542 ml) received RAI (550-2960 MBq). Half of the patients received 0.45 mg of rhTSH prior to the treatment (RAI+rhTSH group) and half did not (RAI group). Patients' blood samples were collected before and 24, 48, and 72 h; 7 and 30 days; and 6, 9, and 12 months after RAI treatment. Serum Tg was measured by immunoradiometric assay, serum anti-Tg by radioimmunoassay, and quantification of circulating Tg mRNA was performed by real-time PCR. The shrinkage of MNG volume was documented by serial computed tomography (CT) scans before, 6 and 12 months after RAI. Peak Tg mRNA and sTg were reached earlier in the RAI+rhTSH group (24 h and 48 h) than in the RAI group (7 days). Both declined after the peak and the lowest levels were observed at 12 months. The mean reduction of the thyroid volume was 19.8% (RAI group) and 30.3% (RAI+rhTSH group) at 6 months (ns) and 32.8% RAI and 52.5% (RAI+rhTSH group) at 12 months (p<0.05). After RAI treatment there was a significant and positive correlation between goiter volume and sTg only in the RAI group (r=0.7; p=0.032). Serum anti-Tg had a transitory and relatively small elevation in 3 and 2 patients, respectively, in the RAI and RAI+rhTSH groups. We concluded that after RAI ablation of MNG there is a rapid release of Tg into the serum possibly from the colloid, which is followed by an elevation of serum Tg mRNA that may be due to an increased release of follicular cells into the blood stream. Both phenomena are enhanced by the use of rhTSH before RAI treatment as a consequence of a more effective and prolonged radiation exposure of the thyroid follicles.
Similar articles
-
Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres.Clin Endocrinol (Oxf). 2004 Mar;60(3):300-8. doi: 10.1046/j.1365-2265.2003.01918.x. Clin Endocrinol (Oxf). 2004. PMID: 15008994 Clinical Trial.
-
High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism.Thyroid. 2009 Sep;19(9):945-51. doi: 10.1089/thy.2008.0394. Thyroid. 2009. PMID: 19678745
-
Radioiodine 131I treatment for large nodular goiter: recombinant human thyrotropin allows the reduction of radioiodine 131I activity to be administered in patients with low uptake.Thyroid. 2011 Jul;21(7):759-64. doi: 10.1089/thy.2010.0088. Epub 2011 May 13. Thyroid. 2011. PMID: 21568727
-
Uses for recombinant human TSH in patients with thyroid cancer and nodular goiter.Clin Endocrinol (Oxf). 2004 Aug;61(2):163-73. doi: 10.1111/j.1365-2265.2004.02025.x. Clin Endocrinol (Oxf). 2004. PMID: 15272910 Review.
-
Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions.Thyroid. 2000 Sep;10(9):767-78. doi: 10.1089/thy.2000.10.767. Thyroid. 2000. PMID: 11041454 Review.
Cited by
-
Preradioactive Iodine Thyroglobulin Levels as Predictors of Metastasis in Well-Differentiated Thyroid Carcinoma Patients.World J Nucl Med. 2022 Sep 5;21(4):296-301. doi: 10.1055/s-0042-1750396. eCollection 2022 Dec. World J Nucl Med. 2022. PMID: 36398311 Free PMC article.
-
Dynamics of serum antithyroglobulin antibodies in patients with differentiated thyroid cancer.Endocrine. 2020 Feb;67(2):387-396. doi: 10.1007/s12020-019-02112-7. Epub 2019 Oct 24. Endocrine. 2020. PMID: 31650394
-
Evaluation of T cell stimulation by thyrotropin-receptor epitopes in Graves' disease.J Endocrinol Invest. 2009 Jan;32(1):52-6. doi: 10.1007/BF03345679. J Endocrinol Invest. 2009. PMID: 19337016
-
Relationship between circulating anti-thyroglobulin antibodies (TgAb) and tumor metabolism in patients with differentiated thyroid cancer (DTC): prognostic implications.J Endocrinol Invest. 2017 Apr;40(4):417-424. doi: 10.1007/s40618-016-0578-6. Epub 2016 Nov 14. J Endocrinol Invest. 2017. PMID: 27844413
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous